JG
TVRD

Jefferies Group’s Tvardi Therapeutics TVRD Stock Holding History

Jefferies Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-417
Closed -$323K – 3116
2019
Q2 		$323K Buy
+417
New +$293K ﹤0.01% 1889
2018
Q1 		– Sell
-517
Closed -$228K – 2792
2017
Q4 		$228K Sell
517
-1,222
-70% -$557K ﹤0.01% 2149
2017
Q3 		$857K Buy
+1,739
New +$871K 0.01% 1358

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Jefferies Group's TVRD Position: Q3 2019 in Review

Jefferies Group sold out of Tvardi Therapeutics (TVRD) in Q3 2019, closing a stake of 6 shares — an estimated $4K sold.

Jefferies Group first reported a position in TVRD in Q2 2017 and held it in 6 quarters. The position peaked at $1.15M in Q2 2017. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • Jefferies Group reported no remaining Tvardi Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Jefferies Group sold 6 Tvardi Therapeutics shares in Q3 2019, an estimated $4K.
  • Jefferies Group first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 6 quarters.
  • Jefferies Group's Tvardi Therapeutics position peaked at $1.15M in Q2 2017.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.